Seoul National University Hospital
Seoul, 03080, South Korea
Location status: Recruiting
NCT Number: NCT05254197
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Seoul, 03080, South Korea
Location status: Recruiting
Non-malignant central nervous system (CNS) tumor accounts for 70% of all primary CNS tumors, and over 300,000 patients were diagnosed with non-malignant CNS tumor per year in the United States. Not much is known about the natural history of non-malignant CNS tumors, as it is often treated immediately upon detection. However, some of them, especially small and asymptomatic non-malignant CNS tumors should not be treated immediately upon diagnosis but are observed and followed-up by repeated magnetic resonance imaging (MRI). This study aims to make a prospective cohort of non-malignant CNS tumors that do not require immediate treatment and to quantitatively analyze which factors are related to the growth of tumors.
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed neoplasms of CNS WHO grade 2 or lower among primary intracranial tumors and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for retrospective cohort
Inclusion criteria
for prospective cohort
Exclusion criteria
Time frame: within 15 years after enrollment
Measured tumor volume in each MRI
Time frame: within 15 years after enrollment
T2 signal intensity of tumor as a ratio to contralateral white matter
Time frame: within 15 years after enrollment
Tumor volume changed on average per year
Time frame: within 15 years after enrollment
Percentage of tumors that change on average per year
Time frame: within 15 years after enrollment
Number of patients who eventually received treatment, such as surgery, radiosurgery, radiotherapy, or hormonal therapy.
Time frame: within 15 years after enrollment
Pre-treatment follow-up period for patients who eventually received treatment, such as surgery, radiosurgery, radiotherapy, or hormonal therapy.
Contact information is provided by the study sponsor or research team.
Seoul National University Hospital
Other
The Risk of Growth in Patients With Non-malignant Brain Tumor: SeOuL cOhort of Brain Tumor MONitoring (SOLOMON) Study
Acronym: SOLOMON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06322342
Acoustic Neuroma, Autoimmune Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT06185686
Brain Diseases, Brain Neoplasms
St Louis, Missouri, United States
View Trial DetailsNCT03213002
Astrocytoma, Brain Cancer
New York, United States
View Trial DetailsNCT05480644
Brain Diseases, Brain Metastases, Adult
Durham, North Carolina, United States
View Trial Details